亲爱的研友该休息了!由于当前在线用户较少,发布求助请尽量完整地填写文献信息,科研通机器人24小时在线,伴您度过漫漫科研夜!身体可是革命的本钱,早点休息,好梦!

ApoE4 lowers the ptau217 threshold for tau aggregation and spread in an allele dose-dependent manner

陶氏病 等位基因 内科学 分泌物 生物 病态的 疾病 内分泌学 淀粉样蛋白(真菌学) 基础(医学) 逻辑回归 淀粉样变性 阿尔茨海默病 化学 队列 医学 等位基因频率 神经科学 海马体 联想(心理学) 细胞生物学
作者
Anna Steward,Anna Dewenter,Fabian Hirsch,Sebastian Niclas Roemer,Zeyu Zhu,Amir Dehsarvi,Davina Biel,Madleen Klonowski,Lukas K. Frontzkowski,Carla Palleis,Johannes S. Gnörich,Martin Dichgans,Günter U. Höglinger,Matthias Brendel,Nicolai Franzmeier
出处
期刊:Brain [Oxford University Press]
卷期号:149 (6): 1902-1914 被引量:6
标识
DOI:10.1093/brain/awaf463
摘要

In Alzheimer's disease, carriage of the apolipoprotein E ε4 (ApoE4) risk allele is linked to faster tau accumulation at lower amyloid-PET levels, thereby accelerating disease progression. However, it remains unclear whether this ApoE4-facilitated transition from amyloidosis to tauopathy is mechanistically promoted by increased secretion of phosphorylated tau (ptau), a key intermediate that drives the amyloid-to-tauopathy transition, or alternatively by increased ptau-driven tau aggregation. Therefore, we investigated where along the amyloid-to-tau axis ApoE4 accelerates tau aggregation and assessed: (i) whether ApoE4 increases ptau secretion; or (ii) whether ApoE4 increases ptau-associated tau aggregation. To this end, we analysed two large-scale APOE-genotyped cohorts covering the full Alzheimer's disease spectrum (Alzheimer's Disease Neuroimaging Initiative; ADNI: n = 201) as well as a preclinical cohort (Anti-Amyloid Treatment in Asymptomatic Alzheimer's and Longitudinal Evaluation of Amyloid Risk and Neurodegeneration study; A4-LEARN: n = 200), integrating baseline amyloid-PET, plasma ptau217 and CSF ptau181 with longitudinal tau-PET. Using linear regression, we tested whether ApoE4 carriage moderates: (i) amyloid-PET-associated plasma ptau217 increases; or (ii) ptau217-associated tau spreading from local epicentres across patient-tailored tau spreading stages. All analyses were independently validated across both cohorts, including an additional replication in an ADNI subset (n = 115) with available CSF ptau181 measures as an alternative marker of ptau secretion. Finally, we used logistic regression to determine ApoE4 allele count-stratified plasma ptau217 thresholds marking early pathological tau-PET increases. We found that ApoE4 did not facilitate amyloid-PET-associated ptau increases, suggesting that amyloid-related ptau secretion is not altered by ApoE4 carriage. Contrastingly, we found that plasma ptau217 elevations were linked to faster tau-PET spread from local epicentres across connected brain regions in an ApoE4 allele dose-dependent manner, independent of amyloid [ADNI/A4-LEARN: mean standardized beta (β) = 0.44/0.56, P < 0.001/P < 0.001]. Lastly, we found that a higher ApoE4 allele count was linked to lower ptau217 thresholds marking transition to tauopathy, i.e. early abnormal tau-PET increases, consistently across both samples (ADNI: 0/1/2 ApoE4 alleles = 0.62/0.34/0.15 pg/ml, representing ∼45% and ∼76% reductions from non-carriers; Fujirebio ptau217 assay; A4-LEARN: 0/1/2 ApoE4 alleles = 0.31/0.23/0.18 pg/ml, representing ∼26% and ∼42% reductions; Eli Lilly ptau217 assay). These findings suggest that ApoE4, i.e. the key genetic risk factor for sporadic Alzheimer's disease, facilitates amyloid-dependent tau aggregation in an allele dose-dependent manner by enhancing the ptau-driven spread of fibrillar tau, leading to an earlier transition from amyloidosis to tauopathy at lower ptau217 levels. This has implications for plasma ptau-based screening approaches and therapeutic timing of anti-amyloid drugs in ApoE4 carriers. Specifically, ApoE4 carriers may require genotype-adjusted ptau thresholds to detect Alzheimer's disease pathophysiology, as well as anti-amyloid treatment at lower ptau levels to prevent the transition to tauopathy, which ultimately drives neurodegeneration and cognitive decline.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
乐观寻芹完成签到,获得积分10
4秒前
9秒前
清爽的孤丝完成签到,获得积分10
12秒前
14秒前
儒雅的新儿完成签到,获得积分10
25秒前
星野的应助被吴金菊采纳,获得10
26秒前
汉堡包的应助被萧雨墨采纳,获得10
30秒前
32秒前
海洋球完成签到,获得积分10
32秒前
38秒前
Hyp完成签到 ,获得积分10
39秒前
40秒前
41秒前
萧雨墨发布了新的文献求助10
43秒前
yuyu完成签到,获得积分10
47秒前
Eric的应助被Bugs采纳,获得10
1分钟前
乐乐的应助被Celia采纳,获得10
1分钟前
fantasy的应助被科研通管家采纳,获得10
1分钟前
fantasy的应助被科研通管家采纳,获得10
1分钟前
1分钟前
Maestro_S的应助被科研通管家采纳,获得10
1分钟前
fantasy的应助被科研通管家采纳,获得10
1分钟前
叶云夕完成签到,获得积分10
1分钟前
尽落完成签到 ,获得积分10
1分钟前
萧雨墨发布了新的文献求助10
1分钟前
奋斗不二完成签到,获得积分10
1分钟前
王露完成签到 ,获得积分10
1分钟前
星辰大海的应助被dart1023采纳,获得10
1分钟前
刘研完成签到,获得积分10
1分钟前
刘研发布了新的文献求助10
1分钟前
1分钟前
一杯茶具完成签到 ,获得积分10
1分钟前
1分钟前
1分钟前
luyiyi发布了新的文献求助10
1分钟前
GTR的我完成签到 ,获得积分10
1分钟前
1分钟前
biubiu发布了新的文献求助10
1分钟前
2分钟前
原长卿发布了新的文献求助10
2分钟前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 2000
Sex, Aging, and Death in a Medieval Medical Compendium: Trinity College Cambridge MS R.14.52, Its Texts, Language, and Scribe 500
高分子基功能界面水蒸发材料与应用研究 500
外场增强的水汽发电研究 500
基于结构调控的功能化水诱导发电材料与器件研究 500
基于界面调控的高效湿气发电材料与器件研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8190075
求助须知:如何正确求助?哪些是违规求助? 9577208
关于积分的说明 21851965
捐赠科研通 7788198
什么是DOI,文献DOI怎么找? 3436234
关于科研通互助平台的介绍 2559936
邀请新用户注册赠送积分活动 2482810